| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Laboratoire d’immunopharmacologie, Institut National de la Santé et de la Recherche Médicale Unité 503, Centre d’Etudes et de Recherche en Virologie et Immunologie, Institut Fédératif de Recherche 128 Biosciences Lyon-Gerland, and
Laboratoire d’Hématologie-Cytogénétique, Institut National de la Santé et de la Recherche Médicale Unité 453, Hopital E. Herriot, Lyon, France
Purine and pyrimidine nucleotides play critical roles in DNA and RNA synthesis as well as in membrane lipid biosynthesis and protein glycosylation. They are necessary for the development and survival of mature T lymphocytes. Activation of T lymphocytes is associated with an increase of purine and pyrimidine pools. However, the question of how purine vs pyrimidine nucleotides regulate proliferation, cell cycle, and survival of primary T lymphocytes following activation has not yet been specifically addressed. This was investigated in the present study by using well-known purine (mycophenolic acid, 6-mercaptopurine) and pyrimidine (methotrexate, 5-fluorouracil) inhibitors, which are used in neoplastic diseases or as immunosuppressive agents. The effect of these inhibitors was analyzed according to their time of addition with respect to the initiation of mitogenic activation. We showed that synthesis of both purine and pyrimidine nucleotides is required for T cell proliferation. However, purine and pyrimidine nucleotides differentially regulate the cell cycle since purines control both G1 to S phase transition and progression through the S phase, whereas pyrimidines only control progression from early to intermediate S phase. Furthermore, inhibition of pyrimidine synthesis induces apoptosis whatever the time of inhibitor addition whereas inhibition of purine nucleotides induces apoptosis only when applied to already cycling T cells, suggesting that both purine and pyrimidine nucleotides are required for survival of cells committed into S phase. These findings reveal a hitherto unknown role of purine and pyrimidine de novo synthesis in regulating cell cycle progression and maintaining survival of activated T lymphocytes.
This article has been cited by other articles:
|
|
 |
|
  R. A. el-Azhary, S. A. Farmer, L. A. Drage, R. S. Rogers III, M. T. McEvoy, M. D. P. Davis, A. G. Bridges, and L. E. Gibson Thioguanine Nucleotides and Thiopurine Methyltransferase in Immunobullous Diseases: Optimal Levels as Adjunctive Tools for Azathioprine Monitoring Arch Dermatol, June 1, 2009; 145(6): 644 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Atreya and M. F Neurath Understanding the delayed onset of action of azathioprine in IBD: are we there yet? Gut, March 1, 2009; 58(3): 325 - 326. [Full Text] [PDF]
|
|
|
|
|
|
S Ben-Horin, I Goldstein, E Fudim, O Picard, Z Yerushalmi, I Barshack, I Bank, Y Goldschmid, S B. Meir, L Mayer, et al. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines Gut, March 1, 2009; 58(3): 396 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mashiko, S. Nagafuchi, M. Kanbe, Y. Obara, Y. Hagawa, T. Takahashi, and K. Katoh Effects of dietary uridine 5'-monophosphate on immune responses in newborn calves J Anim Sci, March 1, 2009; 87(3): 1042 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-X. Sun, M.-S. Dai, and H. Lu Mycophenolic Acid Activation of p53 Requires Ribosomal Proteins L5 and L11 J. Biol. Chem., May 2, 2008; 283(18): 12387 - 12392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. M. Wessels, T. W. J. Huizinga, and H.-J. Guchelaar Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis Rheumatology, March 1, 2008; 47(3): 249 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gaffo, K. G. Saag, and J. R. Curtis Treatment of rheumatoid arthritis Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2451 - 2465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Poppe, I. Tiede, G. Fritz, C. Becker, B. Bartsch, S. Wirtz, D. Strand, S. Tanaka, P. R. Galle, X. R. Bustelo, et al. Azathioprine Suppresses Ezrin-Radixin-Moesin-Dependent T Cell-APC Conjugation through Inhibition of Vav Guanosine Exchange Activity on Rac Proteins J. Immunol., January 1, 2006; 176(1): 640 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Cronstein Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis Pharmacol. Rev., June 1, 2005; 57(2): 163 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tartakover Matalon, A. Ornoy, A. Fishman, L. Drucker, and M. Lishner The effect of 6-mercaptopurine on early human placental explants Hum. Reprod., May 1, 2005; 20(5): 1390 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Thomas, G. M. Myhre, R. Tschumper, R. Sreekumar, D. Jelinek, D. J. McKean, J. J. Lipsky, W. J. Sandborn, and L. J. Egan Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 537 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Quemeneur, L. Beloeil, M.-C. Michallet, G. Angelov, M. Tomkowiak, J.-P. Revillard, and J. Marvel Restriction of De Novo Nucleotide Biosynthesis Interferes with Clonal Expansion and Differentiation into Effector and Memory CD8 T Cells J. Immunol., October 15, 2004; 173(8): 4945 - 4952. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
